Day Zero Diagnostics Inc., an infectious disease diagnostics company utilizing genome sequencing and machine learning to combat the rise of antibiotic-resistant infections, today announced that Gail Marcus has joined the company’s Board of Directors as an independent director.
“We are pleased to welcome Gail Marcus to the Day Zero Diagnostics Board of Directors. Gail’s executive and financial leadership building and growing life sciences companies, and her extensive experience across multiple healthcare sectors including molecular diagnostics, managed care, and life science tools, bring an important diversity of expertise and perspective to our board,” said Jong Lee, co-founder and CEO of Day Zero Diagnostics. “We look forward to Gail’s leadership and guidance as we continue to advance our novel whole genome sequencing-based infectious disease diagnostic technology to address the growing threat of antibiotic resistance.”
Ms. Marcus is a dynamic senior executive, with experience in the public and private sectors. She has held leadership positions in Fortune 100 healthcare companies including various roles of increasing seniority with CIGNA, AdvancePCS/Caremark CVS, United Health Group, Susan G. Komen for the Cure, Calloway Laboratories, and Caris Diagnostics where she was CEO and President. Previously, Ms. Marcus was recognized as one of the Top 100 Women Leaders in Massachusetts by the Commonwealth Institute. Ms. Marcus currently serves on the boards of Cambridge Epigenetix, where she is board chair, as well as PathAI and Natera (Nasdaq: NTRA). Additionally, she is an Assistant Professor of Population Health at Hofstra University. Gail earned a BA magna cum laude from Wesleyan University, an MSE from University of Pennsylvania Moore School of Engineering, an MBA from University of Pennsylvania, Wharton School and a DHA with honors from Medical University of South Carolina.
“I’m excited to work with the Day Zero Diagnostics executive team and board as the company continues to advance its disruptive approach to infectious disease diagnosis, with the mission to help curb the growing global healthcare crisis of antibiotic resistance,” said Gail Marcus. “I am impressed by the company leadership’s experience and steadfast pursuit of their vision for a future where infectious disease and sepsis can be diagnosed more quickly so that clinicians can prescribe the best treatment.”
Day Zero Diagnostics most recently announced an additional $8.2 million in non-dilutive funding from CARB-X for the development of its sequencing based diagnostic system.
Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!
